A 46-year-old patient presented for a second opinion on a mass found within the right breast on a prior outside mammogram. The patient denies any lumps or pain within either breast.
A 46-year-old patient presented for a second opinion on a mass found within the right breast on a prior outside mammogram. The patient denies any lumps or pain within either breast.
Mammography reveals an irregular spiculated mass in the right superior breast, measuring 1.6 cm in diameter (Figures 1 and 2).
On physical exam, no palpable lump is found. On ultrasound, a hypoechoic mass is present within the right 12:00 area measuring 1.0 x 0.8 cm (Figure 3).
MR imaging performed for extent of disease demonstrates the known carcinoma measuring 1.8 cm in the right breast as well as an additional enhancing mass within the left breast (Figure 4). The patient is recalled for second-look ultrasound as well as possible MRI-guided needle biopsy.
At targeted ultrasound the new mass detected on MRI in the left breast is found to measure 8 mm in diameter (Figure 5). The patient consented to undergo ultrasound-guided needle biopsy.
Vacuum-assisted needle core biopsy of the right breast 12:00 area reveals invasive ductal carcinoma. Ultrasound-guided biopsy of the additional mass in the left breast reveals well-differentiated invasive ductal carcinoma. The patient then proceeded to have bilateral lumpectomies.
This case demonstrates the benefit of a complete work-up, including MRI, after diagnosis of breast cancer and the benefit that targeted ultrasound can have in evaluating unsuspected abnormalities found on MRI. The new lesion found on MRI was identified by targeted ultrasound and was therefore able to be biopsied under ultrasound guidance. This is beneficial to both the patient and the facility as the ultrasound procedure is quick and comfortable.
Dr. Destounis is managing partner and a radiologist at Elizabeth Wende Breast Care in Rochester, NY.
Reprinted from DiagnosticImaging.com
Original article: The benefit of a complete breast imaging work up
Related Content
Exogenous hormones and patients at increased risk for breast cancer
October 17th 2023This lecture, presented by Holly J. Pederson, MD, at The Menopause Society 2023 Annual Meeting, looked at combined oral contraceptives in BRCA carriers and other high-risk patients, and hormone therapy in postmenopausal gene carriers as well as other high-risk women.
Read More
Hormone replacement therapy does not increase breast cancer recurrence, mortality in survivors
July 20th 2022An analysis of data from more than 8400 postmenopausal women with a history of early-stage nonmetastatic, ER-positive breast cancer suggests there was no increase in risk of breast cancer recurrence or mortality observed with use of vaginal estrogen therapy or menopausal hormone therapy.
Read More